Table Graph
      published meta-analysis   sensitivity analysis   studies

pyridostigmine in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsFragoso-Saavedra (PISCO), 2020 0.32 [0.13; 0.80] 0.32[0.13; 0.80]Fragoso-Saavedra (PISCO), 202010%188NAnot evaluable deathsdetailed resultsFragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79] 0.33[0.14; 0.79]Fragoso-Saavedra (PISCO), 202010%188NAnot evaluable deaths (time to event analysis only)detailed resultsFragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79] 0.33[0.14; 0.79]Fragoso-Saavedra (PISCO), 202010%188NAnot evaluable death or ventilationdetailed resultsFragoso-Saavedra (PISCO), 2020 0.46 [0.22; 0.96] 0.46[0.22; 0.96]Fragoso-Saavedra (PISCO), 202010%188NAnot evaluable hospital dischargedetailed resultsFragoso-Saavedra (PISCO), 2020 1.13 [0.82; 1.55] 1.13[0.82; 1.55]Fragoso-Saavedra (PISCO), 202010%188NAnot evaluable mechanical ventilationdetailed resultsFragoso-Saavedra (PISCO), 2020 0.85 [0.27; 2.62] 0.85[0.27; 2.62]Fragoso-Saavedra (PISCO), 202010%188NAnot evaluable mechanical ventilation (time to event analysis only)detailed resultsFragoso-Saavedra (PISCO), 2020 0.81 [0.27; 2.42] 0.81[0.27; 2.42]Fragoso-Saavedra (PISCO), 202010%188NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-11-05 18:53 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 959 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons